New biophysical analyses have mapped diverse lipid nanoparticle (LNP) architectures and linked particle shape to delivery performance, while a coordinated academic‑industry effort rapidly manufactured a personalized CRISPR therapy for an infant in months—highlighting convergent advances in nucleic acid delivery. The LNP study from University of Pennsylvania and collaborators used orthogonal techniques to show that particle morphology correlates with tissue targeting and payload delivery efficiency. Separately, clinicians and manufacturers (including Aldevron, IDT and LNP developers) rapidly assembled a tailored CRISPR therapeutic for a child with a urea cycle disorder, coordinating RNA synthesis, safety assays and LNP formulation. LNPs are the lipid‑based carriers that enabled mRNA vaccines and are now central to moving gene‑editing medicines from lab to clinic; both reports emphasize that matching particle design to biological context is critical for clinical success.